GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Suzhou Basecare Medical Corp Ltd (HKSE:02170) » Definitions » ROC %

Suzhou Basecare Medical (HKSE:02170) ROC % : -34.60% (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Suzhou Basecare Medical ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Suzhou Basecare Medical's annualized return on capital (ROC %) for the quarter that ended in Jun. 2024 was -34.60%.

As of today (2025-04-14), Suzhou Basecare Medical's WACC % is 9.61%. Suzhou Basecare Medical's ROC % is -35.34% (calculated using TTM income statement data). Suzhou Basecare Medical earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Suzhou Basecare Medical ROC % Historical Data

The historical data trend for Suzhou Basecare Medical's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suzhou Basecare Medical ROC % Chart

Suzhou Basecare Medical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC %
Get a 7-Day Free Trial -14.84 -52.82 -80.40 -74.48 -42.85

Suzhou Basecare Medical Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -47.56 -78.94 -43.03 -35.81 -34.60

Suzhou Basecare Medical ROC % Calculation

Suzhou Basecare Medical's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-266.218 * ( 1 - 1.51% )/( (376.247 + 847.502)/ 2 )
=-262.1981082/611.8745
=-42.85 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1987.594 - 123.72 - ( 1487.627 - max(0, 127.922 - 1705.889+1487.627))
=376.247

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2076.087 - 196.915 - ( 1031.67 - max(0, 213.577 - 1329.123+1031.67))
=847.502

Suzhou Basecare Medical's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-301.576 * ( 1 - 1.16% )/( (847.502 + 875.256)/ 2 )
=-298.0777184/861.379
=-34.60 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2076.087 - 196.915 - ( 1031.67 - max(0, 213.577 - 1329.123+1031.67))
=847.502

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1935.341 - 161.368 - ( 898.717 - max(0, 213.355 - 1200+898.717))
=875.256

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Suzhou Basecare Medical  (HKSE:02170) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Suzhou Basecare Medical's WACC % is 9.61%. Suzhou Basecare Medical's ROC % is -35.34% (calculated using TTM income statement data). Suzhou Basecare Medical earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Suzhou Basecare Medical ROC % Related Terms

Thank you for viewing the detailed overview of Suzhou Basecare Medical's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Suzhou Basecare Medical Business Description

Traded in Other Exchanges
N/A
Address
BioBay, No. 218 Xinghu Street, Unit 101, Building A3, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215000
Suzhou Basecare Medical Corp Ltd is engaged in providing genetic testing solutions for assisted human reproduction. The company generates revenues from Sales of testing kits, followed by Sales of testing devices, instruments, and consumables. Basecare focuses on the assisted reproductive sector, such as pre-implantation genetic screening and diagnosis, non-invasive prenatal DNA testing, and chromosome abnormalities testing. Geographically the company generates the majority of its revenue from the PRC.
Executives
Orbimed Capital Llc 2102 Investment manager
Lake Bleu Prime Healthcare Master Fund Limited 2201 Interest of corporation controlled by you
Orbimed Partners Master Fund Limited 2101 Beneficial owner
Dawn Capital Fund 2101 Beneficial owner
Dawn Capital Limited 2102 Investment manager
Hh Spr-xiv Cy Holdings Limited 2201 Interest of corporation controlled by you
Hh Spr-xiv Hk Holdings Limited 2101 Beneficial owner
Hh Spr-xiv Holdings L.p. 2201 Interest of corporation controlled by you
Hillhouse Fund Iv, L.p. 2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd. 2102 Investment manager

Suzhou Basecare Medical Headlines

No Headlines